Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Rejects Apple Trade Secret Theft Claims 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Xiaomi Shares Jump on Europe EV Expansion Plan 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
NEWTON, Mass., March 06, 2018 -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, CEO and Founder, will provide a corporate overview at the 30th Annual ROTH Conference, being held March 11-14, 2018 in California.
| Acer Therapeutics Conference Presentation Details | ||||||
| Date: | Tuesday, March 13 | |||||
| Time: | 1:30 pm Pacific Time (4:30 pm Eastern Time) | |||||
| Location: | The Ritz Carlton, Orange County, GREEN - SALON 3 | |||||
| Webcast: | https://acertx.com/investor-relations/events-presentations/ | |||||
About Acer Therapeutics
Acer, headquartered in Newton, MA, is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are few or no FDA-approved treatments: EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS), and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact more than 7,000 patients in the United States. Acer’s product candidates have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FFDCA, that allows an applicant to rely for approval at least in part on third-party data, which is expected to expedite the preparation, submission, and potential approval of a marketing application.
For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-535-7743
[email protected]
